Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods.

Ligand-based and receptor-based methods were used to investigate the binding modes of human adenosine A(2B) antagonists. At first, pharmacophore models were developed based on 140 diverse A(2B) antagonists from literature. Meanwhile, the structural model of A(2B) receptor was built up based on the crystal structure of human A(2A) receptor and validated by Induced Fit docking, Glide-XP and Glide-SP docking. Two models matched each other very well and some important implications were hence obtained. The residues of Phe173 and Glu174 in the second extracellular loop and Asn254 were crucial to the antagonists binding to form pi-pi stacking and hydrogen-bonding interactions. These findings would be very helpful for the discovery of novel and potent A(2B) antagonists.

[1]  K. Jacobson,et al.  Cloning, expression, and characterization of the unique bovine A1 adenosine receptor. Studies on the ligand binding site by site-directed mutagenesis. , 1992, The Journal of biological chemistry.

[2]  M. Loza,et al.  1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: design, synthesis, structure-affinity and structure-selectivity relationships. , 2008, Bioorganic & medicinal chemistry.

[3]  J. Thornton,et al.  Stereochemical quality of protein structure coordinates , 1992, Proteins.

[4]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[5]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[6]  A. Knight,et al.  Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. , 2009, Journal of medicinal chemistry.

[7]  K. Jacobson,et al.  Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. , 2000, Journal of medicinal chemistry.

[8]  Richard M. Jackson,et al.  An evaluation of automated homology modelling methods at low target-template sequence similarity , 2007, Bioinform..

[9]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[10]  K. Klotz,et al.  A new synthesis of sulfonamides by aminolysis of p-nitrophenylsulfonates yielding potent and selective adenosine A2B receptor antagonists. , 2006, Journal of medicinal chemistry.

[11]  J. Shine,et al.  Molecular cloning and expression of an adenosine A2b receptor from human brain. , 1992, Biochemical and biophysical research communications.

[12]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[13]  I. Biaggioni,et al.  Adenosine-Activated Mast Cells Induce IgE Synthesis by B Lymphocytes: An A2B-Mediated Process Involving Th2 Cytokines IL-4 and IL-13 with Implications for Asthma12 , 2004, The Journal of Immunology.

[14]  Bartosz Trzaskowski,et al.  Predicted 3D structures for adenosine receptors bound to ligands: comparison to the crystal structure. , 2010, Journal of structural biology.

[15]  Luhua Lai,et al.  Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. , 2008, Journal of medicinal chemistry.

[16]  Xiaofen Li,et al.  Selective, high affinity A(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines. , 2008, Bioorganic & medicinal chemistry letters.

[17]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[18]  J. Wess,et al.  Site-directed Mutagenesis Identifies Residues Involved in Ligand Recognition in the Human A2a Adenosine Receptor (*) , 1995, The Journal of Biological Chemistry.

[19]  S. Holgate,et al.  Adenosine A2B receptors: a novel therapeutic target in asthma? , 1998, Trends in pharmacological sciences.

[20]  K. Jacobson,et al.  Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides. , 2001, Journal of medicinal chemistry.

[21]  Martin S. Fridson,et al.  Trends , 1948, Bankmagazin.

[22]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[23]  K. Jacobson,et al.  Identification by Site-directed Mutagenesis of Residues Involved in Ligand Recognition and Activation of the Human A3 Adenosine Receptor* , 2002, The Journal of Biological Chemistry.

[24]  K. Klotz,et al.  8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. , 2009, Bioorganic & medicinal chemistry.

[25]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[26]  Ravi Shashi Nayana,et al.  Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. , 2009, Bioorganic & medicinal chemistry.

[27]  G Burnstock,et al.  Receptors for purines and pyrimidines. , 1998, Pharmacological reviews.

[28]  Patrick Scheerer,et al.  Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.

[29]  David A. Lustig,et al.  Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. , 2008, Journal of medicinal chemistry.

[30]  Farag F. Sherbiny,et al.  Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the β2-adrenergic receptor and the human adenosine A2A receptor , 2009, J. Comput. Aided Mol. Des..

[31]  S. Rivkees,et al.  Identification of the Adenine Binding Site of the Human A1 Adenosine Receptor* , 1999, The Journal of Biological Chemistry.

[32]  David M. Ferguson,et al.  A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist , 2006, J. Comput. Aided Mol. Des..

[33]  I Biaggioni,et al.  Adenosine A2B receptors. , 1997, Pharmacological reviews.

[34]  K. Varani,et al.  Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. , 2004, Journal of medicinal chemistry.

[35]  Jing Wei,et al.  3D-Pharmacophore Models for Selective A2A and A2B Adenosine Receptor Antagonists , 2007, J. Chem. Inf. Model..

[36]  A. IJzerman,et al.  Structure‐affinity relationships of adenosine A2B receptor ligands , 2006, Medicinal research reviews.

[37]  A. Pramod,et al.  Quantitative Structure Activity Relationship and Pharmacophore Studies of Adenosine Receptor A2B Inhibitors , 2008, Chemical biology & drug design.

[38]  T. Schwartz,et al.  A second disulfide bridge from the N-terminal domain to extracellular loop 2 dampens receptor activity in GPR39. , 2008, Biochemistry.

[39]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[40]  J. Wess,et al.  Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. , 1996, Molecular pharmacology.

[41]  S. Rasmussen,et al.  The structure and function of G-protein-coupled receptors , 2009, Nature.

[42]  Rao Kalla,et al.  Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonists. , 2006 .

[43]  I. Biaggioni,et al.  Hypoxia Modulates Adenosine Receptors in Human Endothelial and Smooth Muscle Cells Toward an A2B Angiogenic Phenotype , 2004, Hypertension.

[44]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[45]  A. Ivanov,et al.  Molecular modeling and molecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the A2B receptor antagonists. , 2005, Journal of Medicinal Chemistry.

[46]  Gebhard F. X. Schertler,et al.  Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.

[47]  X. García‐Mera,et al.  Synthesis and pharmacological evaluation of novel substituted 9-deazaxanthines as A2B receptor antagonists. , 2010, European journal of medicinal chemistry.

[48]  C. Ledent,et al.  Cardioprotection by Ecto-5′-Nucleotidase (CD73) and A2B Adenosine Receptors , 2007, Circulation.

[49]  A. Tucker,et al.  A1 adenosine receptors. Two amino acids are responsible for species differences in ligand recognition. , 1994, The Journal of biological chemistry.

[50]  A. Castelhano,et al.  [3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors. , 2004, Biochemical pharmacology.

[51]  I. Biaggioni,et al.  A2B Adenosine Receptors Increase Cytokine Release by Bronchial Smooth Muscle Cells , 2004 .

[52]  K. Jacobson,et al.  Quinazolines as adenosine receptor antagonists: SAR and selectivity for A2B receptors. , 2003, Bioorganic & medicinal chemistry.

[53]  K. Jacobson,et al.  Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. , 2002, Journal of medicinal chemistry.

[54]  J. Linden,et al.  Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. , 1997, Molecular pharmacology.